Although we did not observe a decrease in sorafenib-resistant tumor weight, the number of metastases was greatly reduced in MCPIP1-overexpressing tumors, which supported the hypothesis that MCPIP1 may at least partially protect against increased malignancy in sunitinib- and sorafenib-resistant cells and act as a tumor suppressor (Fig. 7D, E). This evidence concerns the gene ZC3H12A and neoplasm.